Jeremy B. Foote

Jeremy B. Foote

Auto-generated profile, based on publicly available information

Jeremy B. Foote

University of Alabama at Birmingham

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WMWilliam M. MacCuaig
William M. MacCuaig
ASAbhilash Samykutty
Abhilash Samykutty
JFJeremy Foote
Jeremy Foote
WLWenyi Luo
Wenyi Luo
AFAlexander Filatenkov
Alexander Filatenkov
LMLacey McNally
Lacey McNally
Nanoparticles are popular tools utilized to selectively deliver drugs and contrast agents for identification and treatment of disease. To determine the usefulness and translational potential of mesoporous silica nanoparticles (MSNs), further evaluations of toxicity are required. MSNs are among the most utilized nano-delivery systems due to ease of synthesis, pore structure, and functionalization. This study aims to elucidate toxicity as a result of intravenous injection of 25 nm MSNs coated with chitosan (C) or polyethylene glycol (PEG) in mice. Following acute and chronic injections, blood was evaluated for standard blood chemistry and complete blood count analyses. Blood chemistry results primarily indicated that no abnormalities were present following acute or chronic injections of MSNs, or C/PEG-coated MSNs. After four weekly administered treatments, vital organs showed minor exacerbation of pre-existing lesions in the 35KPEG-MSN and moderate exacerbation of pre-existing lesions in uncoated MSN and 2KPEG-MSN treatment groups. In contrast, C-MSN treatment groups had minimal changes compared to controls. This study suggests 25 nm MSNs coated with chitosan should elicit minimal toxicity when administered as either single or multiple intravenous injections, but MSNs coated with PEG, especially 2KPEG may exacerbate pre-existing vascular conditions. Further studies should evaluate varying sizes and types of nanoparticles to provide a better overall understanding on the relation between nanoparticles and in vivo toxicity.

25 May 2021 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
HIHayato Iwase
Hayato Iwase
AJAbhijit Jagdale
Abhijit Jagdale
TYTakayuki Yamamoto
Takayuki Yamamoto
MBMohamed H. Bikhet
Mohamed H. Bikhet
HNHuy Q. Nguyen
Huy Q. Nguyen
DCDavid Cooper
David Cooper

19 December 2024 in Cancer Research
Verified
Journal Article
Closed access
JFJeremy B. Foote
Jeremy B. Foote
TMTyler Mattox
Tyler Mattox
AKAdam B. Keeton
Adam B. Keeton
XCXi Chen
Xi Chen
FSForrest T. Smith
Forrest T. Smith
GPGary Piazza
Gary Piazza
Activated RAS is a common driver of cancer that was considered undruggable for decades. Recent advances have enabled the development of RAS inhibitors, but the efficacy of these inhibitors remains limited by resistance. In this study, we developed a pan-RAS inhibitor, ADT-007, (Z)-2-(5-fluoro-1-(4-hydroxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide, that binds nucleotide-free RAS to block GTP activation of effector interactions and MAPK/AKT signaling, resulting in mitotic arrest and apoptosis. ADT-007 potently inhibited the growth of RAS-mutant cancer cells irrespective of the RAS mutation or isozyme. Wild-type RAS (RASWT) cancer cells with GTP-activated RAS from upstream mutations were equally sensitive. Conversely, RASWT cancer cells harboring downstream BRAF mutations and normal cells were essentially insensitive to ADT-007. Sensitivity of cancer cells to ADT-007 required activated RAS and dependence on RAS for proliferation, whereas insensitivity was attributed to metabolic deactivation by UDP-glucuronosyltransferases that were expressed in RASWT and normal cells but repressed in RAS-mutant cancer cells. ADT-007 displayed unique advantages over KRAS mutant-specific, pan-KRAS, and pan-RAS inhibitors that could impact in vivo antitumor efficacy by escaping compensatory mechanisms that lead to resistance. Local administration of ADT-007 showed robust antitumor activity in syngeneic immunocompetent and xenogeneic immune-deficient mouse models of colorectal and pancreatic cancers. The antitumor activity of ADT-007 was associated with the suppression of MAPK signaling and activation of innate and adaptive immunity in the tumor immune microenvironment. Oral administration of ADT-007 prodrug also inhibited tumor growth. Thus, ADT-007 has the potential to address the complex RAS mutational landscape of many human cancers and to improve treatment of RAS-driven tumors. Significance: ADT-007, a first-in-class pan-RAS inhibitor, has unique selectivity for cancer cells with mutant RAS or activated RAS protein and the capability to circumvent resistance to suppress tumor growth, supporting further development of ADT-007 analogs.

4 October 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MSMichael Schultz
Michael Schultz
JSJohn J. Suschak
John J. Suschak
DBDavide Botta
Davide Botta
ASAaron Silva-Sanchez
Aaron Silva-Sanchez
RKRodney Glenn King
Rodney Glenn King
FLFrances E. Lund
Frances E. Lund
The coronavirus disease 2019 (COVID-19) pandemic has illustrated the critical need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive approach for preventing COVID-19 as the nasal mucosa is the site of initial SARS-CoV-2 entry and viral replication prior to aspiration into the lungs. We previously demonstrated that a single intranasal administration of a candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain of the SARS-CoV-2 spike protein (AdCOVID) induced robust immunity in both the airway mucosa and periphery, and completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge. Here we show that a single intranasal administration of AdCOVID limits viral replication in the nasal cavity of K18-hACE2 mice. AdCOVID also induces sterilizing immunity in the lungs of mice as reflected by the absence of infectious virus. Finally, AdCOVID prevents SARS-CoV-2 induced pathological damage in the lungs of mice. These data show that AdCOVID not only limits viral replication in the respiratory tract, but it also prevents virus-induced inflammation and immunopathology following SARS-CoV-2 infection.

13 October 2021 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
JFJeremy B. Foote
Jeremy B. Foote
AJAbhijit Jagdale
Abhijit Jagdale
TYTakayuki Yamamoto
Takayuki Yamamoto
HHHidetaka Hara
Hidetaka Hara
MBMohamed H. Bikhet
Mohamed H. Bikhet
HIHayato Iwase
Hayato Iwase

30 March 2021 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
CTCharles P. Thompson
Charles P. Thompson
AJAbhijit Jagdale
Abhijit Jagdale
GWGregory Walcott
Gregory Walcott
HIHayato Iwase
Hayato Iwase
JFJeremy B. Foote
Jeremy B. Foote
DCDavid Cooper
David Cooper